A5004508109- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Monoclonal and Polyclonal Antibodies Research
- Health Systems, Economic Evaluations, Quality of Life
- Systemic Lupus Erythematosus Research
- Multiple Sclerosis Research Studies
- Urological Disorders and Treatments
- Pediatric Urology and Nephrology Studies
- Urinary and Genital Oncology Studies
- Urinary Bladder and Prostate Research
- Ureteral procedures and complications
- Peripheral Neuropathies and Disorders
- Renal and Vascular Pathologies
- Genital Health and Disease
- Lysosomal Storage Disorders Research
- Urologic and reproductive health conditions
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Patient-Provider Communication in Healthcare
- Rheumatoid Arthritis Research and Therapies
- Statistical Methods in Clinical Trials
- Polyomavirus and related diseases
Beth Israel Deaconess Medical Center
2016-2025
Massachusetts Institute of Technology
2025
Dalhousie University
2005-2025
Certara (United States)
2021-2024
Nationwide Children's Hospital
2022-2024
Integra LifeSciences (United States)
2022-2024
National University Heart Centre Singapore
2014-2024
Harvard University
2013-2024
University of Florida
2024
Hadassah Medical Center
2014-2024
Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results a 96-week phase 3 trial short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.We randomly assigned 1326 an approximate 1:1:1 ratio to receive one two cumulative doses cladribine tablets (either 3.5 mg or 5.25 per kilogram body weight) matching placebo, given four short courses for first 48 weeks, then starting at week and 52 (for total 8 20 days...
Objective To evaluate the efficacy and safety of atacicept, an antagonist B lymphocyte stimulator/ APRIL –mediated cell activation, in patients with systemic lupus erythematosus ( SLE ). Methods ADDRESS II is a 24‐week, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐arm, phase b study evaluating atacicept (ClinicalTrials.gov identifier NCT 01972568). Patients active, autoantibody‐positive receiving standard therapy were randomized (1:1:1) to receive (75 mg or 150 mg)...
To determine if growth hormone (GH) and glutamine (Gln) might allow for a reduction in parenteral nutrition (PN) individuals with short bowel syndrome.
Measuring the health related quality of life patients with prostate cancer in routine clinical practice is hindered by lack instruments enabling efficient, real-time, point care scoring multiple domains. Thus, we developed an instrument for this purpose.The Expanded Prostate Cancer Index Composite Clinical Practice a 1-page, 16-item questionnaire that constructed to measure urinary incontinence, irritation, and bowel, sexual hormonal We eliminated conceptually overlapping items from 3-page...
Over 70% of Canadian carpal tunnel syndrome (CTS) operations are performed outside the main operating room (OR) with field sterility and surgeon-administered pure local anesthesia [LeBlanc et al., Hand 2(4):173-8, 14]. Is OR necessary to avoid infection for this operation? This study evaluates rate in release (CTR) using minor procedure sterility.This is a multicenter prospective reporting CTR setting sterility. Field means prepping hand iodine or chlorhexidine, equivalent single drape,...
Patients with locally advanced prostate cancer have an increased risk of recurrence and mortality. In this phase II trial, we evaluate neoadjuvant enzalutamide leuprolide (EL) or without abiraterone prednisone (ELAP) before radical prostatectomy (RP) in men cancer.Eligible patients had a biopsy Gleason score 4 + 3 = 7 greater, prostate-specific antigen (PSA) greater than 20 ng/mL, T3 disease (by magnetic resonance imaging). Lymph nodes were required to be smaller mm. randomly assigned 2:1...
No AccessJournal of UrologyAdult Urology1 Mar 2018Growth Kinetics Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry Akachimere C. Uzosike, Hiten D. Patel, Ridwan Alam, Zeyad R. Schwen, Mohit Gupta, Michael A. Gorin, H. Johnson, Heather Gausepohl, Mark F. Riffon, Bruce J. Trock, Peter Chang, Andrew Wagner, James M. McKiernan, Mohamad E. Allaf, Phillip Pierorazio UzosikeAkachimere Uzosike , PatelHiten Patel AlamRidwan Alam SchwenZeyad Schwen GuptaMohit...
Objectives To explore the comparative effectiveness of partial nephrectomy ( PN ), radical RN ablative therapies (ablation) and active surveillance AS ) for small renal masses SRM s; tumour diameter ≤4.0 cm) in domains survival, function quality life QoL using prospectively maintained Delayed Intervention Surveillance Small Renal Masses DISSRM Registry. Patients Methods Estimated glomerular filtration rate eGFR was calculated from creatinine values to determine function. measured Short Form...
No AccessJournal of UrologyAdult urology1 Mar 2007Long-Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy—A Propensity Scoring Approachis corrected byErrata Ashutosh Tewari, George Divine, Peter Chang, M. Mendel Shemtov, Matthew Milowsky, David Nanus, Mani Menon TewariAshutosh Tewari , DivineGeorge Divine ChangPeter Chang ShemtovM. Shemtov MilowskyMatthew Milowsky NanusDavid Nanus MenonMani View All...
The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee convened four working groups to recommend core sets patient-reported outcomes be routinely incorporated in clinical trials. Prostate Working Group included physicians, researchers, a patient advocate. group's process 1) systematic literature review determine the prevalence severity symptoms, 2) multistakeholder meeting sponsored by NCI evidence build consensus, 3) postmeeting expert...
Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies significant disease before treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease.
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of antibody with affinity for Trop-2 coupled to SN-38 via hydrolyzable linker. SG approved patients metastatic triple-negative breast cancer (mTNBC) who have received two or more prior chemotherapies (at least one in a setting) and pretreated hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HER2-) cancer.
When using free fat autologous grafts as a filling material was first proposed in 1893 by Neuber,1 the idea rapidly gained enthusiasm and endorsements. Our early experience with transplantation disappointing,2 but even then it clear that could be transferred partial success. Since then, further clinical works Guerrerosantos,3 Coleman,4,5 others6-10 have shown is possible, careful handling of transplanted fat, to improve survival this tissue. We reviewed our recent experiences found several...
Pineal tryptophan, serotonin [5-hydroxytryptamine (5-HT)], N-acetylserotonin, melatonin, 5-hydroxyindoleacetic acid, 5-hydroxytryptophol, 5-methoxytryptophol, and 5-methoxyindoleacetic acid were measured by high pressure liquid chromatography with electrochemical detection. A complete analysis required less than the equivalent of two rat pineal glands. Samples obtained at eight time points. reciprocal physiological relationship was found between oxidation N-acetylation products 5-HT. 5-HT...
Living donor paired exchange programs assume that kidneys from living donors are of comparable quality and anticipated longevity. This study determined actual allograft t(1/2) within different recipient age groups (10-year increments) as a function (5-year increments), juxtaposed these results against the probabilities deceased transplantation, exclusion transplantation (death or removal wait-list).Data US Renal Data System (transplant dates 1988-2003 with follow-up through September 2007)...
We expanded the clinical usefulness of EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) by evaluating its responsiveness to health related quality life changes, defining minimally important differences an individual patient change in each domain and applying it a sexual outcome prediction model.In 1,201 subjects from previously described multicenter longitudinal cohort we modeled scores treatment group before treatment, at short-term long-term followup. considered...